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ABSTRACT 
Non-Alcoholic Fatty Liver Disease (NAFLD) is one of the first hepatic 
manifestations of metabolic syndrome, whose progression can lead to cirrhosis 
and hepatic carcinoma. Interestingly, methyl donor supplementation could 
improve obesogenic diet-induced hepatic triglyceride accumulation.  
The aim of this research is to describe methyl donor effects on a high-fat-
sucrose (HFS) diet in both sexes and epigenetic changes induced on Fatty Acid 
Synthase (FASN) promoter methylation pattern as well as gene expression of 
NAFLD key metabolic genes. 
24 male and 28 female Wistar rats were assigned to three dietary groups: 
control, HFS and HFS supplemented with methyl donors (choline, betaine, 
vitamin B12 and folic acid). After eight weeks of treatment, somatic, biochemical, 
mRNA and epigenetic measurements were performed. 
Rats fed the HFS diet presented an overweight phenotype and alterations in 
plasma biochemical measurements. Methyl donor supplementation reverted the 
HFS-diet-induced hepatic triglyceride accumulation. Analysis of FASN promoter 
cytosine methylation showed changes in both sexes due to the obesogenic diet 
at -1096, -780, -778 and -774 CpG sites with respect to the transcriptional start 
site. Methyl donor supplementation modified DNA methylation at -852, -833, -
829, -743 and -733 CpGs depending on the sex. RT-PCR analysis confirmed 
that FASN expression tended to be altered in males. 
Our findings reinforce the hypothesis that methyl donor supplementation can 
prevent hepatic triglyceride accumulation induced by obesogenic diets in both 
sexes. Changes in liver gene expression profile and epigenetic-mediated 
mechanisms related with FASN DNA hypermethylation could be involved in 
methyl donor-induced NAFLD improvement. 
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INTRODUCTION 
Non-Alcoholic Fatty Liver Disease (NAFLD) is characterized by a triglyceride 
accumulation in hepatocytes that can affect their normal function (Angulo 2002). 
NAFLD prevalence is rising in parallel with the obesity pandemic being related 
to cardiovascular risk (Chen et al. 2010; Edens et al. 2009) and insulin 
resistance (Koot et al. 2011). This disease (NAFLD) is considered the primary 
hepatic manifestation of metabolic syndrome, being the cause of several 
metabolic disorders (Fu et al. 2011). Furthermore, the increase of liver 
triglyceride depots can progress to Non-Alcoholic Steatohepatitis (NASH) and 
later, to cirrhosis, that represents an irreversible stage that may end in hepatic 
carcinoma, liver transplantation or a hepatic-related complication death (Ekstedt 
et al. 2006). 
Besides genetic make-up, unhealthy lifestyles including physical inactivity and 
obesogenic diets are involved in early onset of fat accumulation in the liver 
(Carmiel-Haggai et al. 2005; Gaemers et al. 2011; Moore et al. 2010). At this 
stage, adipokines such as visfatin or proinflammatory cytokines like TNF alpha, 
IL-6 or IL-10  (Dinant et al. 2007; Jarrar et al. 2008) as well as enzymes such as 
Fatty Acid Synthase (FASN), one of the key metabolic genes for de novo 
lipogenesis, may play a role in the pathogenesis of NAFLD. In this pathway 
acetyl CoA carboxylase alpha (ACACA) catalyzes the conversion of acetyl CoA 
to malonyl CoA and FASN catalyzes the conversion of this molecule into long 
chain saturated fatty acids (Strable et al. 2010). Both enzymes are directly 
regulated by sterol regulatory elements binding protein (SREBP), which is a 
regulatory transcription factor (Eberle et al. 2004; Kohjima et al. 2007). Other 
possible mediators in liver steatosis evolution are fatty acid binding proteins 
(FABP), which have roles including fatty acid uptake, transport and metabolism, 
lipases, such as monoglyceride lipase (MGLL) that hydrolyzes triglycerides to 
fatty acids and glycerol, or chemokine ligand 2 (CCl2), a cytokine involved in the 
inflammatory response and atherosclerosis (Bastarrachea RA et al. 2007). 
The research of dietary models of NAFLD and development stages in animal 
models include the assessment of changes by methyl donor group 
administration on the diet, with depletion of choline and methionine (Rinella et 
al. 2008; Vetelainen et al. 2007), or of vitamin B12 and folic acid (Brunaud et al. 
2003). These impairements alter the hepatic epigenetic profile and accelerate 
the progression from slight liver injury to cancer (Pogribny et al. 2009; Starlard-
Davenport et al. 2010). On the contrary, a promethylation cocktail including 
choline, betaine, folic acid and vitamin B12 in a transgenerational model of 
obesity in agouti mice produced phenotypical and epigenetic alterations, where 
the agouti transposon was blocked and heritable obesity minimized (Waterland 
et al. 2008).  
Previous published studies have tested methyl donor dietary supplementation in 
a model of obesity and NAFLD in male adults Wistar rats and have 
demonstrated an improvement in liver fat accumulation (Cordero et al. 2011b). 
The objective of this research is to describe the effects of methyl donor 
supplementation following an obesogenic diet in both sexes with special focus 
on the possible epigenetic changes induced in the methylation pattern of FASN 
promoter as well as gene expression of key metabolic genes in de novo 
lipogenesis and related to lipid metabolism in the liver.   
 
MATERIAL AND METHODS 
Animals, diets and experimental design 
A total of 24 male and 28 female twelve-week-old Wistar rats (initial body weight 
238 ± 5 and 177 ± 2 g respectively ) supplied by the Applied Pharmacobiology 
Center (CIFA, Pamplona,Spain), were housed at 21–23 °C with a 12 h light 
cycle (8 am – 8 pm) and assigned to three different dietary groups; control (C, 
n= 7 males and 9 females), high- fat-sucrose (HFS, n= 9 males and 9 females) 
and high-fat-sucrose supplemented group (HFSsupp, n= 8 males and 10 
females) as previously described (Cordero et al. 2011b). The Control group was 
fed a standard chow diet (2014 Teklad Global 14% Protein Rodent Maintenance 
Diet, Harlan Iberica, Barcelona, Spain) containing 20% of the energy as protein, 
67% as carbohydrate and 13% as lipid in dry weight, whereas HFS groups were 
fed an obesogenic diet (D12451, Research Diets, New Brunswick, NJ, USA) 
containing 20% of the energy as protein, 35% as total carbohydrates (17% 
sucrose) and 45% as fats in dry weight. Finally, a methyl donor supplementation 
cocktail that contained betaine (5 g/kg diet, Sigma-Aldrich, Missouri, USA), 
choline (5.37 g/kg diet, Sigma-Aldrich, Missouri, USA), folic acid (5.5 mg/kg diet, 
Sigma-Aldrich, Missouri, USA) and vitamin B12 (0.5 mg/kg diet, Sigma-Aldrich, 
Missouri, USA) was mixed with HFS powderized pellets to obtain the HFS 
methyl supplemented diet. In order to maintain the same diet consistency, chow 
and HFS pellets were also powderized for the other two dietary groups. After 8 
weeks of ad libitum dietary treatment, the animals were euthanized, blood was 
collected and plasma stored at -20 °C, while samples of liver, adipose depots 
(subcutaneous, retroperitoneal, perigonadal and mesenteric) and 
gastrocnemius muscle were carefully dissected, weighed and stored 
immediately at -80 °C. All the procedures performed agreed with the National 
and Institutional Guidelines of the Animal Care and Use Committee at the 
University of Navarra. 
Serum measurements 
Plasma glucose (HK-CP kit; ABX diagnostic, Montpellier, France), HDL-
cholesterol (HDL direct CP; ABX diagnostic, Montpellier, France), lactate (L-
Lactate; Randox Laboratories Ltd., Crumlin, UK), triglycerides (Triglycerides; 
Randox Laboratories Ltd., Crumlin, UK) and homocysteine (Homocysteine 
Enzymatic Assay; Demeditec Diagnostics, Kiel, Germany) levels were 
measured using automated COBAS MIRA equipment (Roche,Basel, 
Switzerland). Plasma insulin levels were determined by ELISA (Mercodia AB, 
Uppsala, Sweden) in automated TRITURUS equipment (Grifols International 
S.A., Barcelona, Spain). 
Hepatic triglyceride content 
Liver samples were homogenized with a Branson Sonifier 250 (Branson 
Ultrasonic Corporation, Danbury, USA) and triglyceride content was measured 
with a commercial reagent kit (ABX Pentra, Montpellier, France) adapted for the 
COBAS MIRA equipment (Roche, Basel, Switzerland). 
Determination of FASN promoter methylation status 
The quantitative analysis of DNA methylation in the promoter region of FASN 
was performed using an Sequenom EpiTyper approach (Sequenom, CA, USA), 
which relies on base-specific cleavage followed by MALDI-TOF mass 
spectrometry (Milagro et al. 2011). Briefly, genomic DNA was extracted from 
liver samples by using the QIAamp DNA Mini Kit (Qiagen Gmbh, Hilden, 
Germany) and 500 ng were modified by using Epitec Bisulfite Kit (Qiagen 
Gmbh, Hilden, Germany). Primers designed for quantitative analysis of the 
degree of FASN promoter methylation levels were 
aggaagagagAAGTAAGGTTTTGAGGTTTTGGTTT for forward (5′→3′) and 
cagtaatacgactcactatagggagaaggctCTCAAACACCCACCCTTTCTATAAC for 
reverse primers (5′→3′), amplifying from -1,177 to -688 with respect to the 
transcriptional start site. PCR products were excised from agarose gels, 
purified, treated with shrimp alkaline phosphatase to dephosphorylate 
unincorporated dNTPs and later processed by MassArray Matrix Liquid 
Handler. Samples were heat-inactivated and subsequently incubated with 
Transcleave mix for concurrent in vitro transcription and base-specific cleavage. 
After deionization with Sequenom resin, samples were transferred to the 
spectroCHIP array by nanodispensation. Analysis with the Sequenom MALDI-
TOF MS Compact Unit was performed following a 4-point calibration with 
oligonucleotides of different mass provided in the Sequenom kit. Matched peak 
data was exported using EpiTyper software and analyzed (CpGs shown in 
figure 2). 
Real time PCR 
Total RNA was isolated from the liver according to Trizol manufacturer’s 
instructions (Invitrogen, CA, USA) and purified with the RNeasy kit (Qiagen, 
MD, USA). cDNA was synthesized using RT2 Standard Kit as described by 
suppliers (Qiagen, MD, USA). Next, quantitative real-time PCR was performed 
using ABI PRISM 7900 HT Fast Real-Time PCR system (Applied Biosystems, 
TX, USA) with RT2 qPCR commercial primers (Qiagen, MD, USA): SREBPF1 
(XM_213329), ACACA (NM_022193), FASN (NM_017332), MGLL 
(NM_138502), CCL2 (NM_031530) and FABP4 (NM_053365). Fold change 
between groups was calculated using the 2−ΔΔCt method. The gene 
expression levels were normalized with β-actin (ACTB, NM_031144), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, NM_017008) and 
cyclophilin A (PPIA, NM_017101) as internal controls and using Genorm 
Software.  
  
Statistical analysis 
All results are expressed as means ± standard error (SE). Data was evaluated 
separately by sex using one-way ANOVA followed by a DMS post-hoc test for 
multiple comparisons (C, HFS, HFSsupp). The level of probability was set at 
p<0.05 as statistically significant. All analyses were performed using SPSS 15.0 
package for Windows (Chicago, IL, USA). 
 
RESULTS 
As expected, HFS induced an obese phenotype in both sexes (tables 1 and 2), 
although  no relevant differences were found between the rats fed the HFS and 
HFSsupp diets regarding  body weight gain, adiposity or muscle and liver 
weights. However, there was an increase in liver fat accumulation due to HFS 
diet in both sexes (96%, p<0.01 in males and 29%, p<0.05 in females) (Figure 
1). Interestingly, the methyl donor supplementation improved this adverse 
dietary effect and decreased the liver triglyceride content in both males (30%, 
p<0.05) and in females (39%, p<0.01). 
In this trial, the HFS diet induced a disruption of glucose homeostasis in male 
(Table 1) rats but not in females (Table 2). Plasma glucose (17%, p<0.05) and  
insulin levels (112%, p<0.001) were increased in males by the obesogenic diet 
but not in females, whereas plasma lactate levels were also higher in males fed 
a HFS diet (28%, p<0.05) with a reversion due to the methyl supplementation (-
33%, p<0.05). In females a HFS-diet decreased cHDL levels (-29%, p<0.05), 
which was reverted by the methyl donor supplementation (34%, p<0.05). 
The analysis of the DNA methylation patterns of the FASN promoter in males 
(Figure 2A) showed a significant hypomethylated status (p<0.001) at CpG1 in 
the HFS and HFSsupp groups when compared to the control group. 
Interestingly, CpG10-11 was hypermethylated (164%, p<0.01) in the HFSsupp 
as compared to control group, while the HFS group showed an intermediate 
value with no statistical differences with either of the other two groups. The 
obesogenic diet also decreased the methylation levels of  
 
Table 1. Weight-related and plasma measurements of male Wistar rats after eight weeks of dietary 
treatments. 
                    Male Dietary Groups
                     C (n=7)                 HFS (n=9)                HFSsupp (n=8) ANOVA
Weight-related measurements
Weight gain (g) 152.6 ± 7.3 a 191.8 ± 13.0 b 198.8 ± 14.0 b *
Subcutaneous WAT (%) 1.89 ± 0.09 a 3.14 ± 0.19 b 3.10 ± 0.13 b ***
Retroperitoneal WAT (%) 2.83 ± 0.25 a 3.65 ± 0.16 b 3.72 ± 0.21 b *
Epididymal WAT (%) 2.32 ± 0.20 a 3.10 ± 0.11 b 3.32 ± 0.20 b **
Mesenteric WAT (%) 1.06 ± 0.11 a 1.45 ± 0.09 b 1.45 ± 0.13 b *
Liver (%) 2.32 ± 0.03 a 2.37 ± 0.06 a 2.25 ± 0.05 a ns
Gastrocnemius muscle (%) 0.54 ± 0.02 a 0.51 ± 0.01 a 0.51 ± 0.01 a ns
Plasma values
Glucose (mg/dL) 114.5 ± 5.3 a 134.0 ± 4.7 b 122.9 ± 5.4 a,b *
HDL cholesterol (mg/dL) 69.2 ± 3.8 a 72.0 ± 2.8 a 79.6 ± 3.0 a n.s.
Triglycerides (mg/dL) 108.4 ± 8.8 a 100.0 ± 11.3 a 103.1 ± 9.6 a n.s.
Lactate (mg/dL) 25.6 ± 3.2 a,b 32.8 ± 3.2 a 22.1 ± 1.1 b *
Homocysteine (µmol/L) 17.9 ± 1.0 a 18.7 ± 3.1 a 14.3 ± 1.0 a n.s.
Insulin (µU/mL) 20.3 ± 2.4 a 43.1 ± 5.0 b 46.7 ± 3.6 b ***
 
All the results are expressed as the mean ± SE. Statistical analyses were performed using one 
way Anova and Tukey post-hoc test. Different letters (a, b) indicate significant differences 
between groups of at least p < 0.05. (WAT; white adipose tissue, C; control group, HFS; high-
fat-sucrose group, HFSsupp; high-fat-sucrose supplemented with methyl donors group, * p < 
0.05, ** p < 0.01, *** p < 0.001). 
 
 
Table 2. Weight-related and plasma measurements of female Wistar rats after eight weeks of dietary 
treatments. 
                  Female Dietary Groups
            C (n=9)                 HFS (n=9)             HFSsupp (n=10) ANOVA
Weight-related measurements
Weight gain (g) 68.7 ± 5.9 a 102.8 ± 8.9 b 109.4 ± 11.4 b *
Subcutaneous WAT (%) 1.40 ± 0.14 a 2.02 ± 0.26 a,b 2.27 ± 0.28 b *
Retroperitoneal WAT (%) 1.87 ± 0.19 a 2.70 ± 0.29 b 3.09 ± 0.24 b **
Periovaric WAT (%) 2.42 ± 0.30 a 3.53 ± 0.49 a 3.84 ± 0.41 a ns
Mesenteric WAT (%) 1.28 ± 0.18 a 1.63 ± 0.19 a 1.62 ± 0.21 a ns
Liver (%) 2.18 ± 0.03 a 2.14 ± 0.06 a 2.24 ± 0.07 a ns
Gastrocnemius muscle (%) 0.59 ± 0.02 a 0.55 ± 0.03 a 0.51 ± 0.04 a ns
Plasma values
Glucose (mg/dL) 103.4 ± 6.1 a 108.9 ± 3.7 a 119.3 ± 6.7 a n.s.
HDL cholesterol (mg/dL) 56.8 ± 4.3 a 40.4 ± 4.6 b 54.2 ± 4.5 a *
Triglycerides (mg/dL) 86.5 ± 6.9 a 57.7 ± 5.3 a 74.1 ± 13.2 a n.s.
Lactate (mg/dL) 27.8 ± 4.3 a 26.1 ± 3.4 a 34.3 ± 4.7 a n.s.
Homocysteine (µmol/L) 15.6 ± 1.1 a 15.2 ± 0.8 a 14.1 ± 0.9 a n.s.
Insulin (µU/mL) 15.5 ± 4.7 a 16.4 ± 3.3 a 21.2 ± 4.5 a n.s.
 
All the results are expressed as the mean ± SE. Statistical analyses were performed using one 
way Anova and Tukey post-hoc test. Different letters (a, b) indicate significant differences 
between groups of at least p < 0.05. (WAT; white adipose tissue, C; control group, HFS; high-
fat-sucrose group, HFSsupp; high-fat-sucrose supplemented with methyl donors group, * p < 
0.05, ** p < 0.01, *** p < 0.001). 
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Figure 1. Hepatic triglyceride content (in µmol of triglycerides per gram of tissue) in (A) male 
and (B) female Wistar rats. Different letters indicate significant differences between groups of at 
least p < 0.05 (C; control group - white, HFS; high-fat-sucrose group - grey, HFSsupp; high-fat-
sucrose supplemented with methyl donors group - black). 
 
CpG17-18-19 (-50%, p<0.001 HFS and -47%, p<0.001 HFSsupp) in males. In 
females (Figure 2B), CpG1 was hypomethylated by the obesogenic diet 
(p<0.001), as opposed to the area covered by CpG9 and CpG10-11 which 
showed significant changes due to the HFS diet (133%, p<0.05 and 104%, 
p<0.001) and the methyl donor supplementation increased this dietary effect 
(71%, p<0.05 and 34%, p<0.001), showing an additional effect between diet 
and methyl donor supplementation. CpG17-18-19 methylation profile was also 
similar to that presented in males, with a hypomethylation due to the 
obesogenic diet (-40%, p<0.01 HFS and -44%, p<0.01 HFSsupp). There was 
also a hypermethylation of CpG20-21 induced by the methyl donor 
supplementation when compared to both C and HFS diets (767%, p<0.001), 
which showed a lower methylation percentage than the control group (-72%, 
p<0.01). Finally, in females, promoter methylation mean values did not change 
due to diet, but presented a significative increase (40%, p<0.05) when 
comparing HFS with HFS supplemented diet. 
Additionally, the hepatic expression of some key genes involved in lipid 
metabolism-related genes was analyzed by RT-PCR in male Wistar rats (figure 
3). Regarding de novo lipogenesis pathway, significant changes were found in 
ACACA expression (p<0.01), which was 66% higher due to methyl donor 
supplementation. Whereas, SREBPF1 and  
100
80
60
40
20
0
100
80
60
40
20
0
A
B
***
* * ** *
* *
* * * *
* *
* * *
1
GGGTTGACAAGCAAGGCTCTGAGGCTCTGGCTTTTGCTATAGACATGCAGTCAAGGACCACTGACACTACTCCCTCCTTAGCG
CCCCCCCCCCCAAAGCCACTGCCCATAAGGTTGGTCTTAGTGGCCTGGGCCTGTAGTGGAAGGGCAGAAGGAAAGGGATCA
2 3                            4                   
ACTCTGAGCAGTCTGTGTCTTTTTGGTCGGTGAGTTTTCATCATCTCCCGTCCCCAAATTCGATAACCCTTTCAAAAGAGGAAT
5                                                         6    7             8                                             9
TTAAAGGGAGGGAGGGTGAGGGTCCCGGAAACCAGCAACTCAGGGAGGCGCGCAGACGCTCCTTTGTTCCCACCAGGCGG
10      11                        12  13  14 15 16        17  18       19 
GGGAGGGGTGGTATCCCGCTCGCCAGATGGCCGCGCCTGGACACTGAACGGACTCAGGAGACCGCGGCACGCGCCCGTCA
20                      21                                            22
GTGTTCCCTATCCTGCCTACTGCTCTCGTCCCTGCCCGCATCCTGGTCTCCAAGGCGGCCACAGAAAGGGTGGGTGTCTGAG
-1177 -668
TSS
Chr 10, NC_000078.1
104632862-10463371
FASN
M
et
hy
la
tio
n 
le
ve
ls
 (%
)
M
et
hy
la
tio
n 
le
ve
ls
 (%
)
 
Figure 2. Quantitative DNA methylation analysis using MassARRAY system for FASN promoter 
in liver tissue from (A) male and (B) female Wistar rats (TSS; transcriptional start site). The 
results are shown as percentages of methylation. All results are expressed as mean ± SD. 
Different letters indicate significant differences between groups of at least p < 0.05 (Control 
group, white; high-fat-sucrose group, grey; high-fat-sucrose supplemented with methyl donors 
group; black; ** p < 0.01, *** p < 0.001). 
 
FASN only showed a trend to increase (p=0.095 and p=0.082).  The cytokine 
CCL2 was markedly downregulated (-76%, p<0.05) by methyl supplementation 
when compared to controls, with no significant changes induced by HFS diet. 
The lypolitic enzyme MGLL showed a decrease in the mRNA expression levels 
in rats fed the obesogenic diet (-30%, p<0.05). Finally, FABP4 did not show 
significant differences (p=0.093) between the experimental dietary groups. 
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Figure 3. Expression levels (mRNA) of SREBPF1, CACA, FASN, MGLL, CCL2 and FABP4 
measured by RT-PCR in liver from C, HFS and HFSsupp groups in male Wistar rats. Data are 
presented as mean ± SE measured in arbitrary units after normalization with ACTB, GAPDH 
and PPIA. Different letters in the same gene indicate statistically significant differences between 
groups of at least p < 0.05. (control group, white; high-fat-sucrose group, grey; high-fat-sucrose 
supplemented with methyl donors group, black; * p < 0.05, ** p < 0.01). 
 
DISCUSSION 
NAFLD is the main early liver manifestation of the metabolic syndrome, and has 
a close association with obesity (Moore et al. 2010). The increased fat depots 
tend to expand to the visceral organs affecting their functionality (Guri et al. 
2011). In this way, this research has been designed to be focused on the initial 
stage of liver damage, NAFLD, since it could potentially be easier to treat or 
revert than more advanced stages such as NASH or cirrhosis. For that reason, 
it was decided to supplement HFS diet for a period of eight weeks, when obese 
phenotype was at the beginning (Cordero et al. 2011b; Milagro et al. 2006). We 
analyzed all variables according to the sex, as gender is a factor that appears to 
confer differential vulnerability to obesogenic diets (Clark et al. 2011), since 
many of the relevant studies in this field have been conducted only in males. In 
this way, previous investigations have described that obesity-linked disorders 
such as insulin and glucose homeostasis or fat depot distributions differ 
between sexes (Priego et al. 2008). It is also known that steroid hormones can 
play a role in metabolism, accumulation and distribution of the different adipose 
depots (Mayes et al. 2004). Thus, we decided to analyze in a separate way 
males and females and also, to avoid possible disturbances and errors derived 
from hormonal status, we determined gene expression only in male rats. 
Biochemical variables were affected by an obesogenic diet and methyl donor 
supplementation. In males, the increase in insulin levels due to HFS diet (Boque 
et al. 2009) was not enough to control glucose circulating levels. Methyl donor 
supplemented groups presented an intermediate value that suggests a partial 
protection of these methyl substrates on glucose homeostasis. In this sense, 
previous studies during the perinatal nutrition period have shown that maternal 
folic acid supplementation decreases glucose levels in the offspring 
(Chmurzynska et al. 2011), while its depletion, together with low choline levels, 
leads to increased plasma glucose levels (Maloney et al. 2009). However, other 
studies have reported that hepatic steatosis could be associated to increased 
lactate levels (Kalhan et al. 2011). Lactate can be used as a substrate activating 
liver gluconeogenesis, which may contribute to increase glucose levels. 
However, HDL cholesterol, an atherogenic protective factor, is decreased in 
animals fed obesogenic and sucrose enriched diets (Kamgang et al. 2005) 
being known that this molecule removes cholesterol from the peripheral tissues 
transporting it to the liver to be metabolized (Tall 2008). Interestingly, in this 
study a methyl donor cocktail can present a beneficial cardiovascular effect in 
female Wistar rats by increasing cHDL plasma levels during an obesogenic-
proatherogenic dietary treatment.  
The dietary depletion of some micronutrients such as choline or betaine has 
been repeatedly used to generate models of hepatic cirrhosis (Pogribny et al. 
2009; Tryndyak et al. 2011; Vetelainen et al. 2007) and betaine 
supplementation has been studied as a potential hepatoprotective substrate 
(Kathirvel 2010). Folic acid and vitamin B12 have mainly been studied in 
periconceptual periods to prevent neural tube defects and future congenital 
diseases (Ba et al. 2011; Chmurzynska et al. 2011; Dhobale et al. 2011; Wilson 
et al. 2007). The effects of these two promethylating vitamins are related with 
epigenetic changes in the offspring due to the accessibility of the DNA during 
early development (Ozanne et al. 2007). The supplementation cocktail we used, 
was tested in agouti mice and it was found that the agouti transposon was 
blocked by epigenetic silencing, whereas transgenerational heredability of 
obesity and skin colour was interrupted (Waterland et al. 2008). A previous  
investigation of our group (Cordero et al. 2011b) reported that the diet 
supplementation of promethyling agents during adulthood had a positive impact 
effect on hepatic triglyceride accumulation. According to the biochemical onset 
of this disease, different studies have reported that changes in epigenetic marks 
could be related to liver damage. For example, insulin resistance levels in 
patient with NAFLD showed a relation with PPARgamma hepatic methylation 
levels (Sookoian et al. 2010) and maternal hypoproteinic diet is related to 
changes in Igf2 methylation levels in the offspring (Gong et al. 2010). On the 
other hand, obesogenic diets also have the potential to modify the epigenome 
(Campion et al. 2009), mainly during perinatal periods (Martinez et al. 2012; 
Vucetic et al. 2010), but also in adulthood (Lomba et al. 2010). On the contrary, 
the epigenetic pattern may also act as a response element for dietary 
treatments (Cordero et al. 2011a; Milagro et al. 2011). In this context, changes 
in FASN methylation in epididimal adipose tissue induced by the intake of an 
obesogenic diet have been reported in Wistar rats (Lomba et al. 2010). Our 
results concerning this key enzyme of de novo lipogenesis evidenced changes 
in its methylation pattern induced by an obesogenic diet, but also by the methyl 
donor supplementation.  
On the other hand, in NAFLD stage the liver increases the uptake and synthesis 
of fat (Angulo P 2002). Thus, obese rats overexpress genes involved in de novo 
lipogenesis, including SREBPF1, ACACA and FASN. SREBPF1 is an activator 
of many enzymes from this pathway and also for ACACA and FASN (Kohjima et 
al. 2007). In this research we found a correlation (Electronic Supplementary 
Material, figure 4) between SREBPF1 expression and ACACA (p<0.05, 
r=0.477) and also with FASN (p<0.05, r=0.463). These outcomes concluded 
that lipid synthesis in the liver is increased by the obesogenic diet and also by 
methyl donor supplementation. On the other hand, MGLL lipase is involved in 
the activation of intracellular triglyceride hydrolysis to fatty acids and glycerol. In 
our study, MGLL expression profile showed a decrease attributable to HFS 
effect. The impact on lipogenic and lipolytic pathways suggests that methyl 
donor supplementation of a HFS diet increases the total amount of triglycerides 
produced by the liver decreasing their accumulation, so the explanation could 
be described in a lipid storage-mobilization and lipolysis more than on 
synthesis. However, liver FFA uptake is also increased in metabolic syndrome 
and obesity, in such a way that this situation affects their accumulation in the 
liver. The analysis of FABP4 expression levels, a protein implicated in fatty acid 
uptake and upregulated in metabolic syndrome and obesity (Terra et al. 2011), 
revealed no statistical differences. This FABP isoform is highly expressed in 
adipose tissue but it has been also associated in liver with fat accumulation in 
this organ (Westerbacka et al. 2007). Curiously in our study the obesogenic diet 
induced a trend to increase FABP4 gene expression (p=0.093) that was 
reverted by methyl donor supplementation. Finally, although we described 
differences in NAFLD gene expression profile, the pathways that unravel the 
decrease showed in hepatic triglycerides content are still uncertain being 
necessary other studies to deepen into these mechanisms. 
Contrary as expected, methylation levels in FASN promoter did not correlate 
with its gene expression levels. It should be kept in mind that the expression of 
this gene is not only regulated by DNA methylation; there are other epigenetic 
mechanisms such as histone modifications or microRNA regulation that could 
affect mRNA levels (Campion et al. 2009). 
It appears that methyl donors do not influence fat accumulation in adipose 
tissue but it seems that methyl donors affect only the fat accumulation in liver 
(Perseghin 2011). The treatment with methyl donors may not be effective 
against obesity itself, but this dietary supplementation could decrease the 
prevalence of NAFLD as the main hepatic manifestation of metabolic syndrome, 
with all the comorbidities associated to this disease including insulin resistance. 
In this way, even if this work could be an useful tool in the treatment of NAFLD 
there are some limitations that researchers have to evaluate in a cautious and 
appropriate manner, such as the number of individuals, the measurement of 
gene expression only in males or the possibility to include other technique in 
order to validate Sequenom results. 
Summing up, supplementation with methyl donor groups in obesogenic diets 
reverted NAFLD development and associated features in both sexes. One 
possible mechanism involved in this alteration is by affecting the epigenetic 
machinery and by inducing DNA hypermethylation or hypomethylation. Indeed, 
changes in DNA methylation patterns on the FASN gene promoter were 
associated with the obesogenic diet intake and also with the dietary 
supplementation with methyl donors.  
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